View Item 

Show simple item record

Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade
dc.contributor.authorTalaat, N.en_US
dc.contributor.authorYapali, S.en_US
dc.contributor.authorFontana, R. J.en_US
dc.contributor.authorConjeevaram, H. S.en_US
dc.contributor.authorLok, A. S.en_US
dc.date.accessioned2015-05-04T20:36:50Z
dc.date.available2016-07-05T17:27:59Zen
dc.date.issued2015-05en_US
dc.identifier.citationTalaat, N.; Yapali, S.; Fontana, R. J.; Conjeevaram, H. S.; Lok, A. S. (2015). "Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade." Journal of Viral Hepatitis 22(5): 481-488.en_US
dc.identifier.issn1352-0504en_US
dc.identifier.issn1365-2893en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111212
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherhepatitis Cen_US
dc.subject.otherhepatocellular carcinomaen_US
dc.subject.otherhepatitis C treatmenten_US
dc.titleChanges in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decadeen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111212/1/jvh12343.pdf
dc.identifier.doi10.1111/jvh.12343en_US
dc.identifier.sourceJournal of Viral Hepatitisen_US
dc.identifier.citedreferenceMcHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339 ( 21 ): 1485 – 1492.en_US
dc.identifier.citedreferenceVolk ML, Tocco R, Saini S et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50 ( 6 ): 1750 – 1755.en_US
dc.identifier.citedreferenceHolmberg SD, Spradling PR, Moorman AC et al. Hepatitis C in the United States. N Engl J Med 2013; 368 ( 20 ): 1859 – 1861.en_US
dc.identifier.citedreferenceSmith BD, Morgan RL, Beckett GA et al. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157 ( 11 ): 817 – 822.en_US
dc.identifier.citedreferenceKramer JR, Kanwal F, Richardson P et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56 ( 2 ): 320 – 325.en_US
dc.identifier.citedreferenceStepanova M, Kanwal F, El‐Serag HB et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population‐based data from the United States. Hepatology 2011; 53 ( 3 ): 737 – 745.en_US
dc.identifier.citedreferenceBini EJ, Brau N, Currie S et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100 ( 8 ): 1772 – 1779.en_US
dc.identifier.citedreferenceMorrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20 ( 8 ): 754 – 758.en_US
dc.identifier.citedreferenceBruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 ( 3 ): 1020 – 1022.en_US
dc.identifier.citedreferenceWai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38 ( 2 ): 518 – 526.en_US
dc.identifier.citedreferenceAfdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014b; 370 ( 20 ): 1889 – 1898.en_US
dc.identifier.citedreferenceJacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 ( 25 ): 2405 – 2416.en_US
dc.identifier.citedreferencePoordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 ( 13 ): 1195 – 1206.en_US
dc.identifier.citedreferenceMitchell AE, Colvin HM. Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51 ( 3 ): 729 – 733.en_US
dc.identifier.citedreferenceShehab TM, Sonnad SS, Jeffries M et al. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 1999; 30 ( 3 ): 794 – 800.en_US
dc.identifier.citedreferenceClark EC, Yawn BP, Galliher JM et al. Hepatitis C identification and management by family physicians. Fam Med 2005; 37 ( 9 ): 644 – 649.en_US
dc.identifier.citedreferenceRowan PJ, Dunn NJ, El‐Serag HB et al. Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. J Viral Hepat 2007; 14 ( 12 ): 883 – 889.en_US
dc.identifier.citedreferenceSuzuki Y, Ikeda K, Suzuki F et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58 ( 4 ): 655 – 662.en_US
dc.identifier.citedreferenceKanwal F, Hoang T, Kramer JR et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140 ( 4 ): 1182 – 1188 e1.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Hepatocellular carcinoma – United States, 2001–2006. MMWR Morb Mortal Wkly Rep 2010; 59 ( 17 ): 517 – 520.en_US
dc.identifier.citedreferenceChou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158 ( 11 ): 807 – 820.en_US
dc.identifier.citedreferenceMohd Hanafiah K, Groeger J, Flaxman AD et al. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology 2013; 57 ( 4 ): 1333 – 1342.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Vital signs: evaluation of hepatitis C virus infection testing and reporting ‐ eight U.S. sites, 2005‐2011. MMWR. Morb Mortal Wkly Rep 2013; 62 ( 18 ): 357 – 361.en_US
dc.identifier.citedreferenceLy KN, Xing J, Klevens RM et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156 ( 4 ): 271 – 278.en_US
dc.identifier.citedreferenceDenniston MM, Jiles RB, Drobeniuc J et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160 ( 5 ): 293 – 300.en_US
dc.identifier.citedreferenceDavis GL, Alter MJ, El‐Serag H et al. Aging of hepatitis C virus (HCV)‐infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138 ( 2 ): 513 – 521, 21 e1–6.en_US
dc.identifier.citedreferenceVeldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147 ( 10 ): 677 – 684.en_US
dc.identifier.citedreferenceBruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon‐alpha is associated with improved outcome in HCV‐related cirrhosis: a retrospective study. Hepatology 2007; 45 ( 3 ): 579 – 587.en_US
dc.identifier.citedreferenceMorgan TR, Ghany MG, Kim HY et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52 ( 3 ): 833 – 844.en_US
dc.identifier.citedreferencevan der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 ( 24 ): 2584 – 2593.en_US
dc.identifier.citedreferenceZeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014a; 370 ( 17 ): 1604 – 1614.en_US
dc.identifier.citedreferenceFeld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370 ( 17 ): 1594 – 1603.en_US
dc.identifier.citedreferenceZeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014b; 370 ( 21 ): 1993 – 2001.en_US
dc.identifier.citedreferenceAfdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014a; 370 ( 16 ): 1483 – 1493.en_US
dc.identifier.citedreferenceDenniston MM, Klevens RM, McQuillan GM et al. Awareness of infection, knowledge of hepatitis C, and medical follow‐up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001‐2008. Hepatology 2012; 55 ( 6 ): 1652 – 1661.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jvh12343.pdf
Size:
288.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.